Self amplified photonic biosensing platform for microRNA based early diagnosis o...
Self amplified photonic biosensing platform for microRNA based early diagnosis of diseases
The SAPHELY project focuses on the development and the preclinical validation of a nanophotonic-based handheld point-of-care (POC) analysis device for its application to the minimally-invasive early diagnosis of diseases, with a f...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
RBCE-GENODIAGNOSENS
Recuring breast cancer early genetic diagnostic on a chip
159K€
Cerrado
BIOCDx
A miniature Bio photonics Companion Diagnostics platform for...
4M€
Cerrado
TEC2012-34280
INTEGRACION LAB-ON-A-CHIP DE DISPOSITIVOS BIOFOTONICOS PARA...
138K€
Cerrado
SMARTCANCERSENS
Micro nanosensors for early cancer warning system diagnost...
585K€
Cerrado
SERENA
Development of an electrochemical multiSEnsor platform for t...
161K€
Cerrado
RTC-2016-4776-1
NANO_PROST: Desarrollo de una tecnología ultrasensible de se...
Cerrado
Información proyecto SAPHELY
Duración del proyecto: 43 meses
Fecha Inicio: 2014-12-15
Fecha Fin: 2018-07-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The SAPHELY project focuses on the development and the preclinical validation of a nanophotonic-based handheld point-of-care (POC) analysis device for its application to the minimally-invasive early diagnosis of diseases, with a focus in cancer. Disease identification will be based in the fast (<5 minutes), ultra-sensitive (sub-pM) and label-free detection of novel highly-specific microRNA (miRNA) biomarkers, using a small volume of whole blood (<100 μL). This POC analysis device, which will have a low cost (envisaged cost < €3000), will significantly help in the implementation of mass screening programs, with the consequent impact on clinical management, reducing also costs of treatments, and increasing survival rates.
The ultra-high sensitivity required for the direct detection of miRNA biomarkers present in the bloodstream will be achieved by using a novel sensing amplification technique. This technique is based in the use of molecular beacon capture probes with an attached high index nanoparticle, so that the hybridization events are translated into the displacement of these nanoparticles from the sensor surface. The use of this self-amplification technique avoids the use of complex PCR-based amplification methods or labelling processes, which are difficult to implement on-chip.
The cost, size and weight reduction required for deploying an affordable handheld POC device will be achieved by using a novel power-based readout scheme for photonic bandgap sensing structures where the use of expensive, bulky and heavy tuneable lasers and spectrometers is avoided.
Special attention will be paid within the SAPHELY project to explore the potential deployment and commercialisation of the analysis device, by means of the involvement of relevant academic and industrial partners, as well as end users.